152 related articles for article (PubMed ID: 17965551)
1. Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice.
Urano K; Suzuki S; Machida K; Eguchi N; Sawa N; Kikuchi K; Hattori Y; Usui T
J Toxicol Sci; 2007 Oct; 32(4):367-75. PubMed ID: 17965551
[TBL] [Abstract][Full Text] [Related]
2. Use of IC tags in short-term carcinogenicity study on CB6F1 TGrasH2 mice.
Urano K; Suzuki S; Machida K; Sawa N; Eguchi N; Kikuchi K; Fukasawa K; Taguchi F; Usui T
J Toxicol Sci; 2006 Dec; 31(5):407-18. PubMed ID: 17202757
[TBL] [Abstract][Full Text] [Related]
3. Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.
Takaoka M; Sehata S; Maejima T; Imai T; Torii M; Satoh H; Toyosawa K; Tanakamaru ZY; Adachi T; Hisada S; Ueda M; Ogasawara H; Matsumoto M; Kobayashi K; Mutai M; Usui T
Toxicol Pathol; 2003; 31(2):191-9. PubMed ID: 12696579
[TBL] [Abstract][Full Text] [Related]
4. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice.
Yamamoto S; Mitsumori K; Kodama Y; Matsunuma N; Manabe S; Okamiya H; Suzuki H; Fukuda T; Sakamaki Y; Sunaga M; Nomura G; Hioki K; Wakana S; Nomura T; Hayashi Y
Carcinogenesis; 1996 Nov; 17(11):2455-61. PubMed ID: 8968063
[TBL] [Abstract][Full Text] [Related]
5. Twenty-six-Week carcinogenicity study of chloroform in CB6F1 rasH2-transgenic mice.
Sehata S; Maejima T; Watanabe M; Ogata S; Makino T; Tanaka K; Manabe S; Takaoka M
Toxicol Pathol; 2002; 30(3):328-38. PubMed ID: 12051550
[TBL] [Abstract][Full Text] [Related]
6. Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice.
Adachi T; Kuwamura Y; Fujiwara T; Tanimoto N; Nishimura T; Koguchi A; Kobayashi K; Sasaki Y; Yamaguchi C; Honda T; Kawashima K; Yuasa H; Yamamura T; Inui T
J Toxicol Sci; 2002 Aug; 27(3):147-63. PubMed ID: 12238139
[TBL] [Abstract][Full Text] [Related]
7. Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice.
Torii M; Itoh F; Yabuuchi K; Ohno K; Kominami G; Hirano K; Tasaki T; Nara H
J Toxicol Sci; 2001 May; 26(2):61-73. PubMed ID: 11429969
[TBL] [Abstract][Full Text] [Related]
8. 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice.
Cho WS; Jeong J; Choi M; Park SN; Han BS; Son WC
Arch Toxicol; 2011 Jan; 85(1):59-66. PubMed ID: 20358181
[TBL] [Abstract][Full Text] [Related]
9. Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: evaluation of husbandry and housing factors.
Holden HE; Stoll RE; Spalding JW; Tennant RW
J Appl Toxicol; 1998; 18(1):19-24. PubMed ID: 9526830
[TBL] [Abstract][Full Text] [Related]
10. Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.
Suguro M; Numano T; Kawabe M; Doi Y; Imai N; Mera Y; Tamano S
Toxicol Pathol; 2017 Apr; 45(3):427-434. PubMed ID: 28421967
[TBL] [Abstract][Full Text] [Related]
11. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
12. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
Mitsumori K; Koizumi H; Nomura T; Yamamoto S
Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
[TBL] [Abstract][Full Text] [Related]
13. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
14. Establishment and Validation of an Ultra-Short-Term Skin Carcinogenicity Bioassay Using Tg-rasH2 Mice.
Kawabe M; Urano K; Suguro M; Hara T; Kageyama Y; Mera Y; Tsutsumi H
Vet Pathol; 2020 Jan; 57(1):192-199. PubMed ID: 31221040
[TBL] [Abstract][Full Text] [Related]
15. The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups.
Paranjpe MG; Denton MD; Elbekai RH
Toxicol Pathol; 2014 Oct; 42(7):1153-7. PubMed ID: 23960167
[TBL] [Abstract][Full Text] [Related]
16. A 26-week carcinogenicity study of 2-amino-3-methylimidazo[4,5-f]quinoline in rasH2 mice.
Okamura M; Moto M; Muguruma M; Ito T; Jin M; Kashida Y; Mitsumori K
Toxicol Pathol; 2006; 34(2):199-205. PubMed ID: 16537296
[TBL] [Abstract][Full Text] [Related]
17. Carcinogenic comparative study on rasH2 mice produced by two breeding facilities.
Machida K; Urano K; Yoshimura M; Tsutsumi H; Nomura T; Usui T
J Toxicol Sci; 2008 Oct; 33(4):493-501. PubMed ID: 18827450
[TBL] [Abstract][Full Text] [Related]
18. Toxicology and carcinogenesis studies of pyrogallol (CAS No. 87-66-1) in F344/N rats and B6C3F1/N mice (dermal studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2013 Feb; (574):1-167. PubMed ID: 23518671
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of Spontaneous Tumors in Tg.rasH2 Mice in 26-week Carcinogenicity Studies Conducted at a Single Test Facility during 2004 to 2012 and 2013 to 2018.
Paranjpe MG; Belich JL; Mann PC; McKeon ME; Elbekai RH; Brown CM; Patrick DJ
Toxicol Pathol; 2019 Jan; 47(1):18-25. PubMed ID: 30407148
[TBL] [Abstract][Full Text] [Related]
20. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Koizumi H; Wakana S; Hioki K; Mitsumori K; Kurokawa Y; Hayashi Y; Nomura T
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):57-69. PubMed ID: 9539005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
